Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification

Richard P. Ebstein; Daniel Moscovich; Shulamit Zeevi; Zamir Amiri; Bernard Lerer

doi:10.1016/0165-1781(87)90026-6

Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification

Richard P. Ebstein
, Daniel Moscovich
, Shulamit Zeevi
, Zamir Amiri
, Bernard Lerer

Department of Psychology

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

LiCl in vitro markedly inhibits forskolin-stimulated human platelet adenylate cyclase activity by competing competitively with Mg^2⁺ for a site on the catalytic subunit. The sensitivity of platelet membrane adenylate cyclase to lithium inhibition for individual manic patients was determined by the Dixon plot procedure: marked individual differences in sensitivity to lithium were observed pretreatment (0.66 mM-3.15 mM LiCl). After 3 weeks of continuous treatment with lithium in vivo a significant decrease in adenylate cyclase affinity for lithium was observed (pretreatment average K_i = 1.38 ± 0.92 mM vs. treatment average K_i = 2.98 ± 1.35 mM LiCl, n = 10). The clinical implications of these findings relating to chronic lithium exposure are discussed.

Original language	English
Pages (from-to)	221-228
Number of pages	8
Journal	Psychiatry Research
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/0165-1781(87)90026-6
State	Published - Jul 1987

Keywords

LiCl
adenylate cyclase
cyclic adenosine monophosphate
mania
second messenger

Access to Document

10.1016/0165-1781(87)90026-6

Cite this

@article{b2a371323afc497c994a8e87517f90fe,

title = "Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification",

abstract = "LiCl in vitro markedly inhibits forskolin-stimulated human platelet adenylate cyclase activity by competing competitively with Mg2+ for a site on the catalytic subunit. The sensitivity of platelet membrane adenylate cyclase to lithium inhibition for individual manic patients was determined by the Dixon plot procedure: marked individual differences in sensitivity to lithium were observed pretreatment (0.66 mM-3.15 mM LiCl). After 3 weeks of continuous treatment with lithium in vivo a significant decrease in adenylate cyclase affinity for lithium was observed (pretreatment average Ki = 1.38 ± 0.92 mM vs. treatment average Ki = 2.98 ± 1.35 mM LiCl, n = 10). The clinical implications of these findings relating to chronic lithium exposure are discussed.",

keywords = "LiCl, adenylate cyclase, cyclic adenosine monophosphate, mania, second messenger",

author = "Ebstein, \{Richard P.\} and Daniel Moscovich and Shulamit Zeevi and Zamir Amiri and Bernard Lerer",

year = "1987",

month = jul,

doi = "10.1016/0165-1781(87)90026-6",

language = "אנגלית",

volume = "21",

pages = "221--228",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity

T2 - Postreceptor modification of second messenger signal amplification

AU - Ebstein, Richard P.

AU - Moscovich, Daniel

AU - Zeevi, Shulamit

AU - Amiri, Zamir

AU - Lerer, Bernard

PY - 1987/7

Y1 - 1987/7

N2 - LiCl in vitro markedly inhibits forskolin-stimulated human platelet adenylate cyclase activity by competing competitively with Mg2+ for a site on the catalytic subunit. The sensitivity of platelet membrane adenylate cyclase to lithium inhibition for individual manic patients was determined by the Dixon plot procedure: marked individual differences in sensitivity to lithium were observed pretreatment (0.66 mM-3.15 mM LiCl). After 3 weeks of continuous treatment with lithium in vivo a significant decrease in adenylate cyclase affinity for lithium was observed (pretreatment average Ki = 1.38 ± 0.92 mM vs. treatment average Ki = 2.98 ± 1.35 mM LiCl, n = 10). The clinical implications of these findings relating to chronic lithium exposure are discussed.

AB - LiCl in vitro markedly inhibits forskolin-stimulated human platelet adenylate cyclase activity by competing competitively with Mg2+ for a site on the catalytic subunit. The sensitivity of platelet membrane adenylate cyclase to lithium inhibition for individual manic patients was determined by the Dixon plot procedure: marked individual differences in sensitivity to lithium were observed pretreatment (0.66 mM-3.15 mM LiCl). After 3 weeks of continuous treatment with lithium in vivo a significant decrease in adenylate cyclase affinity for lithium was observed (pretreatment average Ki = 1.38 ± 0.92 mM vs. treatment average Ki = 2.98 ± 1.35 mM LiCl, n = 10). The clinical implications of these findings relating to chronic lithium exposure are discussed.

KW - LiCl

KW - adenylate cyclase

KW - cyclic adenosine monophosphate

KW - mania

KW - second messenger

UR - https://www.scopus.com/pages/publications/0023197793

U2 - 10.1016/0165-1781(87)90026-6

DO - 10.1016/0165-1781(87)90026-6

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 2819913

AN - SCOPUS:0023197793

SN - 0165-1781

VL - 21

SP - 221

EP - 228

JO - Psychiatry Research

JF - Psychiatry Research

IS - 3

ER -

Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: Postreceptor modification of second messenger signal amplification

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this